 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- STC-15 / STORM Therap
Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies. (Hall A; Poster Bd #: 65) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2988;
P1
Early biomarker data provide proof of mechanism in target engagement, strong activation of innate immune responses and correlation of pharmacological activity with clinical response. The study is ongoing and expansion cohorts are underway to further evaluate PK/PD, safety and clinical efficacy at optimized pharmacologically active doses.
- || STC-15 / STORM Therap
Trial completion date, Trial primary completion date, Metastases: Oral Administration of STC-15 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Jan 23, 2024
P1, N=66, Recruiting, Sponsor: STORM Therapeutics LTD
The study is ongoing and expansion cohorts are underway to further evaluate PK/PD, safety and clinical efficacy at optimized pharmacologically active doses. Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2024
- || STC-15 / STORM Therap
Trial completion date, Trial primary completion date, Metastases: Oral Administration of STC-15 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Oct 10, 2023
P1, N=66, Recruiting, Sponsor: STORM Therapeutics LTD
Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2024 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
- STC-15 / STORM Therap
STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_567;
- | STC-15 / STORM Therap
New P1 trial, Metastases: Oral Administration of STC-15 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Oct 18, 2022
P1, N=66, Recruiting, Sponsor: STORM Therapeutics LTD
- STC-15 / STORM Therap
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1676;
These data provide the rationale for the development of STC-15 both as monotherapy and in combination with checkpoint inhibition for the treatment of solid tumour malignancies. A Phase I, First-in-Human clinical trial is planned to begin in 2022 Ethics Approval Animal welfare for this study complies with the UK Animals Scientific Procedures Act 1986 (ASPA) in line with Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes.
- STC-15 / STORM Therap
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_480;
These data provide the rationale for the development of STC-15 both as monotherapy and in combination with checkpoint inhibition for the treatment of solid tumour malignancies. A Phase I, First-in-Human clinical trial is planned to begin in 2022.